

# Yoichiro Natori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4759571/publications.pdf>

Version: 2024-02-01

55  
papers

1,090  
citations

687363

13  
h-index

414414

32  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2246  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19: A global transplant perspective on successfully navigating a pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 1773-1779.	4.7	189
2	COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. <i>Transplantation Reviews</i> , 2021, 35, 100588.	2.9	159
3	A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 67, 1322-1329.	5.8	145
4	A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1698-1704.	5.8	141
5	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 617-631.	5.8	67
6	Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients. <i>Transplantation</i> , 2017, 101, 1449-1454.	1.0	50
7	Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1392-1397.	5.8	46
8	Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida. <i>Transplantation</i> , 2021, 105, e139-e141.	1.0	32
9	Effects of Tocilizumab in COVID-19 patients: a cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 964.	2.9	30
10	T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients. <i>Scientific Reports</i> , 2020, 10, 10104.	3.3	27
11	Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13625.	1.7	24
12	Surgical Site Infections After Liver Transplantation: Prospective Surveillance and Evaluation of 250 Transplant Recipients in Canada. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1084-1090.	1.8	15
13	Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. <i>Blood Advances</i> , 2020, 4, 4618-4622.	5.2	15
14	Risk factors for surgical site infection after kidney and pancreas transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1042-1048.	1.8	14
15	Kidney transplantation during coronavirus 2019 pandemic at a large hospital in Miami. <i>Transplant Infectious Disease</i> , 2020, 22, e13416.	1.7	14
16	Is it safe to perform abdominal transplantation from SARS-CoV-2 polymerase chain reaction positive donors?. <i>Transplant Infectious Disease</i> , 2021, 23, e13688.	1.7	12
17	Incidence, Outcomes, and Long-term Immune Response to Tuberculosis in Organ Transplant Recipients. <i>Transplantation</i> , 2019, 103, 210-215.	1.0	11
18	Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2020, 221, 53-62.	4.0	10

#	ARTICLE	IF	CITATIONS
19	Reinfection with SARS-CoV-2 in solid organ transplant recipients: Incidence density and convalescent immunity prior to reinfection. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	10
20	Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13207.	1.7	9
21	Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2709-2718.	4.7	7
22	When is it Safe to perform Abdominal Transplantation in patients with prior SARS-CoV-2 infection: A Case Series. <i>Clinical Transplantation</i> , 2021, , e14370.	1.6	7
23	Is the outcome of SARS-CoV-2 infection in solid organ transplant recipients really similar to that of the general population?. <i>American Journal of Transplantation</i> , 2021, 21, 1670-1671.	4.7	6
24	Antimicrobial resistance and recurrent bacterial urinary tract infections in hospitalized patients following kidney transplantation: A single-center experience. <i>Transplant Infectious Disease</i> , 2020, 22, e13337.	1.7	5
25	Lower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1017.e1-1017.e1.	1.2	5
26	Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 6364-6367.	5.2	5
27	Cefazolin plus ertapenem and heart transplantation as salvage therapy for refractory LVAD infection due to methicillin-susceptible <i>Staphylococcus aureus</i> : A case series. <i>Journal of Cardiac Surgery</i> , 2021, 36, 4786-4788.	0.7	5
28	Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1210-1216.	5.8	5
29	Small bowel transplantation from SARS-CoV-2 respiratory PCR positive donors: Is it safe?. <i>Transplant Infectious Disease</i> , 2021, 23, e13752.	1.7	4
30	Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2019, 4, 1705-1716.	0.8	3
31	Treatment of latent tuberculosis infection with short-course regimens in potential living kidney donors. <i>Transplant Infectious Disease</i> , 2020, 22, e13244.	1.7	3
32	The economic impact of increased length of stay associated with surgical site infections in liver transplantation on Canadian healthcare costs. <i>Clinical Transplantation</i> , 2021, 35, e14155.	1.6	3
33	Impact of COVID-19 on living donor liver and kidney transplantation programs in Japan in 2020. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	3
34	<i>Mycobacterium abscessus</i> Infections in Solid Organ Transplant Recipients: Single-Center Experience in the United States, 2013-2018. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	3
35	Rapid reinfection of severe acute respiratory syndrome coronavirus 2 confirmed with sequencing in a solid organ transplant recipient. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	2
36	Hepatitis flare in hepatitis B core antibody positive kidney recipients treated with rituximab. <i>Transplant Infectious Disease</i> , 2020, 22, e13211.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Viral Kinetics and Outcomes of Adenovirus Reactivation Following Allogeneic Hematopoietic Cell Transplant or CAR-T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S331.	2.0	1
38	Clinical Presentation and Outcomes of COVID-19 Following Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S351.	1.2	1
39	Infections in LVAD patients. <i>Journal of Cardiac Surgery</i> , 2022, 37, 2090-2091.	0.7	1
40	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa320.	0.9	0
41	Discordance Between Radiologic Findings and Molecular Testing in Patients With Underlying Hematologic Malignancy and Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa372.	0.9	0
42	Correlation of intraoperative donor duodenal-segment swab cultures with the subsequent occurrence of surgical site infections in kidney and pancreas transplant recipients. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1178-1183.	1.8	0
43	Screening of human Cytomegalovirus among solid organ transplant candidates at a large transplant center. <i>Clinical Transplantation</i> , 2020, 34, e13825.	1.6	0
44	Influenza Infections in Solid Organ and Stem Cell Transplant Recipients. , 2021, , 709-724.		0
45	Influenza Infections in Solid Organ and Stem Cell Transplant Recipients. , 2020, , 1-16.		0
46	1611. Evaluating Clinical Outcomes and Efficacy of Daptomycin in Combination with a Beta-Lactam for the Treatment of Vancomycin-Resistant <i>Enterococcus</i> (VRE) Bacteremia. <i>Open Forum Infectious Diseases</i> , 2020, 7, S799-S800.	0.9	0
47	110. Impact of Diagnostic and Antimicrobial Stewardship on Time-to-Appropriate Therapy and Clinical Outcomes in Multi-Drug Resistant <i>Pseudomonas</i> Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, S69-S70.	0.9	0
48	1103. Respiratory Virus Infections In Solid Organ Transplant Recipients: A Single Center Experience. <i>Open Forum Infectious Diseases</i> , 2020, 7, S581-S582.	0.9	0
49	942. Pulmonary Infections in Intestinal Transplant Recipients with Preexisting Pulmonary Nodules. <i>Open Forum Infectious Diseases</i> , 2021, 8, S564-S564.	0.9	0
50	476. A Global Survey of Countermeasures Against the COVID-19 Pandemic Among Solid Organ Transplant Centers. <i>Open Forum Infectious Diseases</i> , 2021, 8, S339-S340.	0.9	0
51	1347. Comparison Between SARS-Cov-2, non-SARS-Cov-2 Coronavirus, Influenza and RSV Infections Among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S760-S761.	0.9	0
52	933. Incidence and Risk Factors for <i>Cytomegalovirus</i> Infection in Intestinal Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S559-S559.	0.9	0
53	1336. Outcomes of COVID-19 in Recent Kidney Transplants Recipients at a Large Transplant Center in Miami. <i>Open Forum Infectious Diseases</i> , 2021, 8, S756-S756.	0.9	0
54	True effect of monoclonal antibody for COVID-19 in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, , .	4.7	0

#	ARTICLE	IF	CITATIONS
55	Response to Letters regarding "Reinfection with SARS-CoV-2 in solid organ transplant (SOT) recipients: Incidence density and convalescent immunity prior to reinfection". Transplant Infectious Disease, 2022, 24, .	1.7	0